MetLife Investment Management’s Amneal Pharmaceuticals AMRX Stock Holding History

MetLife Investment Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.72M	Buy	99,455 +18,404	+23%	+$252K	0.01%	1240
2026 Q1	$1.01M	Buy	81,051 +803	+1%	+$10.8K	0.01%	1389
2025 Q4	$1.01M	Sell	80,248 -8,848	-10%	-$101K	﹤0.01%	1426
2025 Q3	$892K	Sell	89,096 -5,841	-6%	-$52.4K	﹤0.01%	1512
2025 Q2	$768K	Hold	94,937	–	–	﹤0.01%	1454
2025 Q1	$796K	Buy	94,937 +298	+0.3%	+$2.49K	﹤0.01%	1475
2024 Q4	$750K	Buy	94,639 +2,297	+2%	+$19.3K	﹤0.01%	1570
2024 Q3	$768K	Hold	92,342	–	–	﹤0.01%	1549
2024 Q2	$586K	Buy	92,342 +35,634	+63%	+$226K	﹤0.01%	1634
2024 Q1	$344K	Sell	56,708 -12,102	-18%	-$68.2K	﹤0.01%	1893
2023 Q4	$418K	Hold	68,810	–	–	﹤0.01%	1798
2023 Q3	$290K	Hold	68,810	–	–	﹤0.01%	1981
2023 Q2	$213K	Buy	68,810 +40,998	+147%	+$87.3K	﹤0.01%	2233
2023 Q1	$38.7K	Sell	27,812 -18,734	-40%	-$37.3K	﹤0.01%	2732
2022 Q4	$92.6K	Sell	46,546 -9,482	-17%	-$21.3K	﹤0.01%	2623
2022 Q3	$113K	Buy	56,028 +26,741	+91%	+$74.9K	﹤0.01%	2624
2022 Q2	$93.1K	Sell	29,287 -29,026	-50%	-$105K	﹤0.01%	2734
2022 Q1	$243K	Buy	58,313 +36,668	+169%	+$162K	﹤0.01%	2237
2021 Q4	$104K	Sell	21,645 -18,760	-46%	-$93.5K	﹤0.01%	2395
2021 Q3	$216K	Hold	40,405	–	–	﹤0.01%	2044
2021 Q2	$207K	Hold	40,405	–	–	﹤0.01%	2155
2021 Q1	$272K	Buy	40,405 +19,388	+92%	+$107K	﹤0.01%	1875
2020 Q4	$96K	Sell	21,017 -13,661	-39%	-$60.5K	﹤0.01%	2228
2020 Q3	$135K	Sell	34,678 -20,595	-37%	-$88.1K	﹤0.01%	2077
2020 Q2	$263K	Hold	55,273	–	–	﹤0.01%	1737
2020 Q1	$192K	Hold	55,273	–	–	﹤0.01%	1720
2019 Q4	$266K	Buy	55,273 +14,736	+36%	+$51.2K	﹤0.01%	1821
2019 Q3	$118K	Hold	40,537	–	–	﹤0.01%	2240
2019 Q2	$291K	Sell	40,537 -81,074	-67%	-$829K	﹤0.01%	1804
2019 Q1	$1.72M	Buy	121,611 +81,074	+200%	+$1.07M	0.01%	1345
2018 Q4	$548K	Hold	40,537	–	–	0.01%	1311
2018 Q3	$900K	Buy	+40,537	New	+$853K	0.01%	1184

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

MetLife Investment Management's AMRX Position: Q2 2026 in Review

MetLife Investment Management increased its Amneal Pharmaceuticals (AMRX) stake by 23% in Q2 2026, buying an estimated $252K and bringing the position to 99,455 shares worth $1.72M. The position accounts for 0.01% of the portfolio, ranked #1240.

MetLife Investment Management first reported a position in AMRX in Q3 2018 and has held it in 32 quarters since. The position peaked at $1.72M in Q1 2019. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

MetLife Investment Management held 99,455 shares of Amneal Pharmaceuticals worth $1.72M as of Q2 2026.
MetLife Investment Management bought 18,404 Amneal Pharmaceuticals shares in Q2 2026, an estimated $252K.
Amneal Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1240 holding.
MetLife Investment Management first reported a position in Amneal Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
MetLife Investment Management's Amneal Pharmaceuticals position peaked at $1.72M in Q1 2019.
311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.